{"drugs":["Allegra","Allegra ODT","Fexofenadine Hydrochloride"],"mono":{"0":{"id":"923709-s-0","title":"Generic Names","mono":"Fexofenadine Hydrochloride"},"1":{"id":"923709-s-1","title":"Dosing and Indications","sub":[{"id":"923709-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Idiopathic urticaria, chronic:<\/b> 60 mg ORALLY twice daily OR 180 mg ORALLY once daily with water (manufacturer dosing); if symptoms persist after 2 weeks, may increase up to 4 times the standard dose (guideline dosing)<\/li><li><b>Seasonal allergic rhinitis:<\/b> 60 mg ORALLY twice daily or 180 mg once daily with water<\/li><\/ul>"},{"id":"923709-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in children less than 6 months of age<\/li><li>orally disintegrating tablets (ODT) not approved for children under 6 years of age<\/li><li><b>Idiopathic urticaria, chronic:<\/b> (6 months to 2 years of age) 15 mg ORALLY twice daily (manufacturer dosing); if symptoms persist after 2 weeks, may increase up to 4 times the standard dose (guideline dosing)<\/li><li><b>Idiopathic urticaria, chronic:<\/b> (2 to 11 years of age) 30 mg ORALLY twice daily (manufacturer dosing); if symptoms persist after 2 weeks, may increase up to 4 times the standard dose (guideline dosing)<\/li><li><b>Idiopathic urticaria, chronic:<\/b> (12 years or older) 60 mg ORALLY twice daily OR 180 mg ORALLY once daily with water (manufacturer dosing); if symptoms persist after 2 weeks, may increase up to 4 times the standard dose (guideline dosing)<\/li><li><b>Seasonal allergic rhinitis:<\/b> 2 to 11 years, 30 mg ORALLY twice daily with water<\/li><li><b>Seasonal allergic rhinitis:<\/b> 12 years and older, 60 mg ORALLY twice daily or 180 mg once daily with water<\/li><\/ul>"},{"id":"923709-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> adults and children 12 yrs and older, starting dose, 60 mg once daily<\/li><li><b>renal impairment:<\/b> 2 to 11 yrs, starting dose, 30 mg once daily<\/li><li><b>renal impairment:<\/b> 6 months to 2 years, starting dose, 15 mg once daily<\/li><\/ul>"},{"id":"923709-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Idiopathic urticaria, chronic<\/li><li>Seasonal allergic rhinitis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Hymenoptera immunotherapy, Pretreatment<\/li><li>Perennial allergic rhinitis<\/li><\/ul>"}]},"3":{"id":"923709-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923709-s-3-9","title":"Contraindications","mono":"hypersensitivity to fexofenadine or any of the ingredients <br\/>"},{"id":"923709-s-3-10","title":"Precautions","mono":"<ul><li>concurrent administration of aluminum- and magnesium-containing antacid within 15 minutes; decrease fexofenadine absorption<\/li><li>concurrent consumption of fruit juices, such as grapefruit, orange, and apple; decrease fexofenadine bioavailability and exposure<\/li><\/ul>"},{"id":"923709-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Fexofenadine: C (FDA)<\/li><li>Fexofenadine: B2 (AUS)<\/li><\/ul>"},{"id":"923709-s-3-12","title":"Breast Feeding","mono":"<ul><li>Fexofenadine: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Fexofenadine: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"923709-s-4","title":"Drug Interactions","sub":{"1":{"id":"923709-s-4-14","title":"Major","mono":"<ul><li>Eliglustat (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Tocophersolan (theoretical)<\/li><\/ul>"},"2":{"id":"923709-s-4-15","title":"Moderate","mono":"<ul><li>Aluminum Carbonate, Basic (probable)<\/li><li>Aluminum Hydroxide (probable)<\/li><li>Aluminum Phosphate (probable)<\/li><li>Dihydroxyaluminum Aminoacetate (probable)<\/li><li>Dihydroxyaluminum Sodium Carbonate (probable)<\/li><li>Magaldrate (probable)<\/li><li>Magnesium Carbonate (probable)<\/li><li>Magnesium Hydroxide (probable)<\/li><li>Magnesium Oxide (probable)<\/li><li>Magnesium Trisilicate (probable)<\/li><li>St John's Wort (probable)<\/li><\/ul>"}}},"5":{"id":"923709-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Stomach ache (2.1%)<\/li><li><b>Musculoskeletal:<\/b>Backache (2.1% to 2.5%)<\/li><li><b>Neurologic:<\/b>Dizziness (2.1%), Headache (4.8% to 10.3%), Somnolence<\/li><li><b>Other:<\/b>Fatigue, Pain in limb (2.1%)<\/li><\/ul>"},"6":{"id":"923709-s-6","title":"Drug Name Info","sub":{"0":{"id":"923709-s-6-17","title":"US Trade Names","mono":"<ul><li>Allegra<\/li><li>Allegra ODT<\/li><\/ul>"},"2":{"id":"923709-s-6-19","title":"Class","mono":"<ul><li>Antihistamine, Less-Sedating<\/li><li>Butyrophenone<\/li><li>Respiratory Agent<\/li><\/ul>"},"3":{"id":"923709-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"923709-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"923709-s-7","title":"Mechanism Of Action","mono":"Fexofenadine hydrochloride inhibits the release of histamine from mast cells and selectively antagonizes peripheral histamine(1)-receptor activity.<br\/>"},"8":{"id":"923709-s-8","title":"Pharmacokinetics","sub":[{"id":"923709-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, 2.6 h<\/li><li>Bioavailability: not yet established<\/li><\/ul>"},{"id":"923709-s-8-24","title":"Distribution","mono":"Protein binding: 60% to 70% <br\/>"},{"id":"923709-s-8-25","title":"Metabolism","mono":"Approximately 5% <br\/>"},{"id":"923709-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 80% unchanged<\/li><li>Renal: 11% unchanged<\/li><li>Dialyzable: no (hemodialysis), 1.7% removed<\/li><\/ul>"},{"id":"923709-s-8-27","title":"Elimination Half Life","mono":"<ul><li>14.4 h<\/li><li>Mild to moderate renal impairment (creatinine clearance 41 mL\/min to 80 mL\/min): 59% longer<\/li><li>Severe renal impairment (creatinine clearance 11 mL\/min to 40 mL\/min): 72% longer<\/li><li>Patients on dialysis (creatinine clearance less than or equal to 10 mL\/min): 31% longer<\/li><\/ul>"}]},"9":{"id":"923709-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>do not take concurrently or closely in time with aluminum and magnesium containing antacids<\/li><li>for orally disintegrating tablets only; take on an empty stomach; allow it to disintegrate on the tongue, then swallow with or without water, and do not chew; should not remove from the original blister package until the time of administration <\/li><li>(pediatrics) shake suspension well before measuring dose<\/li><\/ul>"},"10":{"id":"923709-s-10","title":"Monitoring","mono":"<ul><li>improvement in rhinitis<\/li><li>improvement in urticaria<\/li><li>CNS effects (eg stimulation)<\/li><\/ul>"},"11":{"id":"923709-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 30 MG, 60 MG, 180 MG<br\/><\/li><li><b>Allegra Allergy<\/b><br\/>Oral Tablet: 60 MG, 180 MG<br\/><\/li><li><b>Allegra ODT<\/b><br\/>Oral Tablet, Disintegrating: 30 MG<br\/><\/li><li><b>Allegra<\/b><br\/><ul><li>Oral Suspension: 30 MG\/5 ML<\/li><li>Oral Tablet: 60 MG, 180 MG<\/li><\/ul><\/li><li><b>Children's Allegra Allergy<\/b><br\/><ul><li>Oral Suspension: 30 MG\/5 ML<\/li><li>Oral Tablet: 30 MG<\/li><li>Oral Tablet, Disintegrating: 30 MG<\/li><\/ul><\/li><li><b>Children's Allergy Fexofenadine HCl<\/b><br\/>Oral Suspension: 30 MG\/5 ML<br\/><\/li><li><b>Good Neighbor Pharmacy Allergy Relief<\/b><br\/>Oral Tablet: 180 MG<br\/><\/li><li><b>Leader Aller-Ease<\/b><br\/>Oral Tablet: 180 MG<br\/><\/li><li><b>Rite Aid Allergy Relief<\/b><br\/>Oral Tablet: 180 MG<br\/><\/li><li><b>Sunmark Fexofenadine Hydrochloride<\/b><br\/>Oral Tablet: 180 MG<br\/><\/li><li><b>TopCare 24-Hour Fexofenadine Hydrochloride<\/b><br\/>Oral Tablet: 180 MG<br\/><\/li><li><b>WAL-FEX ALLERGY<\/b><br\/>Oral Tablet: 180 MG<br\/><\/li><li><b>Wal-Fex<\/b><br\/>Oral Tablet: 180 MG<br\/><\/li><\/ul>"},"12":{"id":"923709-s-12","title":"Toxicology","sub":[{"id":"923709-s-12-31","title":"Clinical Effects","mono":"<b>FEXOFENADINE<\/b><br\/>OVERDOSE: No human data.  Animals: does NOT cause QTc prolongation or dysrhythmias. ADVERSE EFFECTS: nausea, dysmenorrhea, drowsiness & fatigue in &lt;2% of patients. <br\/>"},{"id":"923709-s-12-32","title":"Treatment","mono":"<b>FEXOFENADINE <\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: PREHOSPITAL:  Prehospital gastrointestinal decontamination is not recommended. HOSPITAL:  Administer activated charcoal if the overdose is recent, the patient is not vomiting, and is able to maintain airway.<\/li><li>Antidote: None.<\/li><li>Monitoring of patient: Obtain baseline ECG, cardiac monitoring with significant overdose. Monitor CNS function.<\/li><li>Ventricular arrhythmia: Limited data. Ventricular dysrhythmias have been reported in one patient during therapeutic use. Monitor rhythm following a significant exposure.<\/li><\/ul>"},{"id":"923709-s-12-33","title":"Range of Toxicity","mono":"<b>FEXOFENADINE<\/b><br\/>Recommended dose (&gt;12 years) -  60 milligrams, twice daily. No lethal human dose has been reported. Animal data: suggests low toxicity. <br\/>"}]},"13":{"id":"923709-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized.<\/li><li>This drug may cause dyspepsia, dizziness, headache, somnolence, dysmenorrhea, or fatigue.<\/li><li>Take drug with water. Do not take with fruit juices (grapefruit, orange, apple).<\/li><li>Patient should avoid administration of aluminum- or magnesium-containing antacids within 30 min before or after taking drug.<\/li><\/ul>"}}}